Hong Kong Renal Registry Report 2012

SummaryThis report examined the characteristics and trends of dialysis and renal transplant patients among the resident population of Hong Kong who were managed by hospitals or dialysis centers of the Hospital Authority, and accounted for approximately 95% of all patients receiving renal replacement therapies (RRTs) in the territory. Patients receiving RRTs solely in the private sector were not included in this report. Data trends from 1996 to 2011 are presented. In 2011, 1115 new patients were accepted into RRT programs, and the incident rate was 157 patients per million populations (pmp). An increasing trend was noted. The incident rate was 95.1 pmp at the commencement of the annual report in 1996. The point prevalence on December 31, 2012 was 8197 with a prevalence rate of 1152.5 pmp. Overall, there were 3573 patients (43.6%) on peritoneal dialysis (PD) and 1246 patients (15.2%) on hemodialysis (HD), and 3378 patients (41.2%) were living with a functioning renal transplant. The PD/HD ratio was 74.2:25.8. The “PD First” policy was continued. The overall mortality rate among RRT patients was 9.95 patients per 100 patient-years exposed. There was a decreasing trend in mortality among PD patients. Infection and cardiovascular complications were the most common causes of death. Renal transplant was the modality with the best survival rates. The 5 years cumulative patient survival rate for patients on transplant treatment was 89.6%, whereas the corresponding patient survival rates for PD and HD patients were 50.7% and 55.7%, respectively. More than 70% of RRT patients with reports on rehabilitation were active and had normal daily activities

Selectivity and Mechanism of Hydrogen Atom Transfer by an Isolable Imidoiron(III) Complex

This article discusses a mechanistic study of hydrogen atom transfer by an isolable iron (III) imido complex, LᴹᵉFeNAd (Lᴹᵉ = bulky β-diketiminate ligand, 2,4-bis(2,6-diisopropylphenylimido)pentyl; Ad = 1-adamantyl)

[[alternative]]Parallel Representatives of the Parent-son Epistolary Genre

[[issue]]2

Lanthanide–Cyclen–Camptothecin Nanocomposites for Cancer Theranostics Guided by Near-Infrared and Magnetic Resonance Imaging

We have devised a molecular-to-micellar strategy to incorporate a lanthanide nanoplatform for the delivery of an anticancer drug that simultaneously offers hybrid near-infrared (NIR) and magnetic resonance imaging (MRI) capabilities with defined lanthanide(III) ratio control. This cancer-selective lanthanide-based self-assembled nanocomposite (LnNPs) has been synthesized by conjugating lanthanide–cyclen complexes (cycLn) with a well-known drug–camptothecin (CPT) through a redox-sensitive disulfide bond (−ss–). By accurately controlling the ratio of Gd(III) and Yb(III) complexes, we prepared hybrid nanoparticles (Gd/YbNPs) with both NIR and MR imaging properties. The enhanced stability at ultralow critical aggregation concentrations (CACs), simultaneous optical and MR imaging, improved delivery/chemotherapeutic efficiency, and cancer cell selectivity of such nanomicellar theranostic prodrugs in vitro and in vivo have thus been achieved and validated. The work provides a blueprint combining a stimuli-activated NIR luminescence and real-time MR imaging into a safe and biocompatible nanoplatform for selective cancer treatment